BRCA2 is a gene that helps repair damaged DNA inside your cells. Everyone has two copies of it, one inherited from each parent. When the gene works normally, it acts as a tumor suppressor, fixing broken DNA strands before they can lead to uncontrolled cell growth. When someone inherits a harmful mutation in one copy of BRCA2, their cells lose some of that repair ability, which substantially raises the lifetime risk of several cancers.
What the BRCA2 Gene Does
Inside the nucleus of your cells, the BRCA2 protein teams up with other proteins to mend double-strand breaks in DNA. These breaks happen constantly from normal processes like cell division, as well as from environmental exposures such as UV light and radiation. The protein’s main job is in a repair process called homologous recombination, which uses the undamaged copy of a DNA strand as a template to fix the broken one with high accuracy.
This makes BRCA2 one of the body’s key guardians of genetic stability. When both copies of the gene are functioning, damaged DNA gets repaired cleanly. When one copy carries a harmful mutation and the second copy is lost or damaged over time in a particular cell, that cell can no longer fix double-strand breaks properly. Errors accumulate, and the cell becomes far more likely to turn cancerous.
Cancer Risks for Women With a BRCA2 Mutation
Breast cancer is the most well-known risk. Women in the general population have roughly a 13% lifetime chance of developing breast cancer. For women who carry a harmful BRCA2 variant, that risk climbs dramatically, with estimates typically in the range of 45% to 70% by age 70 or 80 depending on the study and the specific mutation.
Ovarian cancer risk also rises significantly. In the general population, the lifetime risk is about 1.2%. For BRCA2 carriers, it’s considerably higher. Pancreatic cancer is another concern: carriers face about three times the average risk, translating to roughly a 2% to 3% absolute risk by age 80. That’s still a relatively low number in absolute terms, but meaningful compared to the general population rate.
Cancer Risks for Men
BRCA2 mutations aren’t just a women’s health issue. Men who carry a harmful variant face elevated risks of their own, particularly for prostate cancer and male breast cancer.
For prostate cancer, the numbers are striking: 19% to 61% of men with a harmful BRCA2 change will develop prostate cancer by age 80, and these cancers tend to be more aggressive than average. Male breast cancer, while still uncommon, occurs in roughly 1.8% to 7.1% of men with a BRCA2 mutation by age 70. In the general male population, breast cancer is extremely rare, affecting fewer than 1 in 1,000 men over a lifetime. BRCA2 mutations also contribute to the same elevated pancreatic cancer risk seen in women.
How BRCA2 Mutations Are Inherited
BRCA2 follows an autosomal dominant inheritance pattern for cancer risk. That means if one of your parents carries a harmful variant, you have a 50% chance of inheriting it. The mutation can come from either your mother or your father, and men pass it on just as readily as women do.
Certain populations carry specific BRCA2 mutations at higher rates. Among people of Ashkenazi Jewish descent, three founder mutations in BRCA1 and BRCA2 combined are common enough that broader genetic testing has been recommended even outside families with multiple cancer diagnoses. In one community survey of over 5,000 Jewish participants, 10% of Jewish women diagnosed with breast cancer in their forties carried one of these mutations.
Screening Recommendations for Carriers
If you’re found to carry a harmful BRCA2 variant, screening recommendations are more intensive and start earlier than for the general population. The American College of Radiology recommends that women with BRCA2 mutations begin annual breast MRI between ages 25 and 30. Annual mammograms can be delayed until age 40 as long as you’re getting the recommended MRI screening. If MRI isn’t available or feasible, mammography is recommended starting at age 30.
For men with BRCA2 mutations, prostate cancer screening discussions typically begin earlier than the standard age of 50. Given the elevated risk of aggressive disease, earlier and more frequent screening with PSA testing is often part of the management plan.
Risk-Reducing Options
For women who carry a BRCA2 mutation, preventive surgery is one of the most effective ways to lower cancer risk. Risk-reducing removal of the ovaries and fallopian tubes is recommended between ages 40 and 45 for BRCA2 carriers. This is slightly later than the recommendation for BRCA1 carriers (35 to 40), because BRCA2-related ovarian cancers tend to develop at a somewhat older age. The surgery dramatically reduces ovarian cancer risk and also lowers breast cancer risk when performed before menopause, since it reduces hormone exposure.
Preventive mastectomy is another option some carriers choose, though enhanced screening is a reasonable alternative for women who prefer it. The decision is deeply personal and depends on your specific risk level, family history, and preferences.
How BRCA2 Status Affects Treatment
A BRCA2 mutation doesn’t just affect your cancer risk. It also opens the door to targeted therapies if cancer does develop. A class of drugs called PARP inhibitors exploits the exact weakness that makes BRCA2-mutated cells dangerous in the first place.
Here’s the logic: BRCA2-deficient cancer cells already can’t repair double-strand DNA breaks properly. PARP is a separate protein that handles a different type of DNA repair. When you block PARP with a drug, cancer cells that also lack working BRCA2 have no backup repair system left. They accumulate so much DNA damage that they die, while normal cells (which still have one functioning BRCA2 copy) survive. This concept is called synthetic lethality.
Four PARP inhibitors have received FDA approval for clinical use. In clinical trials, these drugs outperformed standard chemotherapy for BRCA-mutated breast cancers, improving survival rates in both early-stage and metastatic disease. They’re also approved for certain ovarian, pancreatic, and prostate cancers linked to BRCA mutations.
Who Should Consider Genetic Testing
You don’t need a family full of cancer diagnoses to consider BRCA2 testing. Testing is generally recommended if you have a close relative (parent, sibling, or child) with a known BRCA mutation, a personal or family history of breast cancer before age 50, ovarian cancer at any age, male breast cancer, pancreatic cancer combined with other BRCA-associated cancers in the family, or Ashkenazi Jewish ancestry with any breast or ovarian cancer in the family.
Testing is a simple blood or saliva test. If a mutation is found, your close relatives can then be tested for that specific variant, which is faster and less expensive than broad genetic screening. A negative result in someone whose family has a known mutation is genuinely reassuring, meaning their cancer risk returns to the general population level. A negative result without a known family mutation is harder to interpret, since it could mean the family’s cancer risk comes from a gene that wasn’t tested or from non-genetic factors entirely.